Mei-Ching Liu

2.4k total citations
21 papers, 509 citations indexed

About

Mei-Ching Liu is a scholar working on Oncology, Pathology and Forensic Medicine and Cancer Research. According to data from OpenAlex, Mei-Ching Liu has authored 21 papers receiving a total of 509 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 8 papers in Pathology and Forensic Medicine and 7 papers in Cancer Research. Recurrent topics in Mei-Ching Liu's work include Breast Cancer Treatment Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and HER2/EGFR in Cancer Research (5 papers). Mei-Ching Liu is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), Cancer Treatment and Pharmacology (5 papers) and HER2/EGFR in Cancer Research (5 papers). Mei-Ching Liu collaborates with scholars based in Taiwan, United States and Spain. Mei-Ching Liu's co-authors include An‐Chen Feng, Andrew T. Huang, James Jer‐Min Jian, Szu-Yun Leu, Skye Hongiun Cheng, Mei-Hua Tsou, Jason Chia‐Hsien Cheng, Carlos H. Barrios, Li‐Han Hsu and Marla Jo Brickman and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and International Journal of Radiation Oncology*Biology*Physics.

In The Last Decade

Mei-Ching Liu

21 papers receiving 503 citations

Peers

Mei-Ching Liu

ONCOL

CR

PRM

MB

PFM

Laurence Venat‐Bouvet France

Shan Zheng China

J. Crawford United States

Valeria Forestieri Italy

Andreas duBois Germany

Pankaj Khandelwal United States

Emma Zattarin Italy

Ángel Martínez-Agulló Spain

Christophe Zemmour France

Alisha Stein United States

Laurence Venat‐Bouvet France

Mei-Ching Liu

366 ×1.1

ONCOL

181 ×1.0

CR

138 ×1.1

PRM

96 ×0.9

MB

45 ×0.5

PFM

Citations per year, relative to Mei-Ching Liu Mei-Ching Liu (= 1×) peers Laurence Venat‐Bouvet

Countries citing papers authored by Mei-Ching Liu

Since Specialization

Citations

This map shows the geographic impact of Mei-Ching Liu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mei-Ching Liu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mei-Ching Liu more than expected).

Fields of papers citing papers by Mei-Ching Liu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mei-Ching Liu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mei-Ching Liu. The network helps show where Mei-Ching Liu may publish in the future.

Co-authorship network of co-authors of Mei-Ching Liu

This figure shows the co-authorship network connecting the top 25 collaborators of Mei-Ching Liu. A scholar is included among the top collaborators of Mei-Ching Liu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mei-Ching Liu. Mei-Ching Liu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

1.

Hickish, Tamas, Ajay Mehta, Mei-Ching Liu, et al.. (2022). Afatinib alone and in combination with vinorelbine or paclitaxel, in patients with HER2-positive breast cancer who failed or progressed on prior trastuzumab and/or lapatinib (LUX-Breast 2): an open-label, multicenter, phase II trial. Breast Cancer Research and Treatment. 192(3). 593–602. 9 indexed citations

2.

Huang, Chiun‐Sheng, Youngsen Yang, Ava Kwong, et al.. (2021). Trastuzumab emtansine (T-DM1) versus trastuzumab in Chinese patients with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted therapy for HER2-positive breast cancer in the phase 3 KATHERINE study. Breast Cancer Research and Treatment. 187(3). 759–768. 9 indexed citations

3.

Brufsky, Adam, Sung‐Bae Kim, Thierry Velu, et al.. (2016). Cobimetinib (C) + paclitaxel (P) as first-line treatment in patients (pts) with advanced triple-negative breast cancer (TNBC): Updated results and biomarker data from the phase 2 COLET study.. Journal of Clinical Oncology. 34(15_suppl). 1074–1074. 5 indexed citations

4.

Bianchini, Giampaolo, Tadeusz Pieńkowski, Young‐Hyuck Im, et al.. (2016). Residual disease after HER2-directed therapies in the neosphere study: Modulation of tumor lymphocyte infiltration (TIL) and prognosis.. Journal of Clinical Oncology. 34(15_suppl). 517–517. 1 indexed citations

5.

Liu, Mei-Ching, et al.. (2015). A General Cutoff Level Combined With Personalized Dynamic Change of Serum Carcinoembryonic Antigen Can Suggest Timely Use of FDG PET for Early Detection of Recurrent Colorectal Cancer. Clinical Nuclear Medicine. 40(10). e465–e469. 10 indexed citations

6.

Gianni, Luca, Tadeusz Pieńkowski, Young‐Hyuck Im, et al.. (2015). Five-year analysis of the phase II NeoSphere trial evaluating four cycles of neoadjuvant docetaxel (D) and/or trastuzumab (T) and/or pertuzumab (P).. Journal of Clinical Oncology. 33(15_suppl). 505–505. 20 indexed citations

7.

Cheng, Skye Hung‐Chun, Cheng‐Fang Horng, Stella Y. Tsai, et al.. (2015). Long-term survival and stage I breast cancer subtypes. SHILAP Revista de lepidopterología. 3(1). 1–8. 17 indexed citations

8.

Cheng, Skye Hung‐Chun, Cheng‐Fang Horng, Stella Y. Tsai, et al.. (2014). In-Depth Evaluation of the AJCC 2010 Staging System for Luminal-like Breast Cancer-An Analysis from a Free-Standing Cancer Hospital. 30(1). 21–34. 1 indexed citations

9.

Cheng, Skye Hung‐Chun, Stella Y. Tsai, Cheng‐Fang Horng, et al.. (2012). Validating a Prognostic Scoring System for Postmastectomy Locoregional Recurrence in Breast Cancer. International Journal of Radiation Oncology*Biology*Physics. 85(4). 953–958. 16 indexed citations

10.

You, Dong‐Ling, et al.. (2011). Underperformance of Gallium-67 Scan is Greater in Relapse Than in Initial Staging, Compared With FDG PET. Clinical Nuclear Medicine. 36(10). 867–871. 1 indexed citations

11.

Barrios, Carlos H., Mei-Ching Liu, Soo Chin Lee, et al.. (2010). Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer. Breast Cancer Research and Treatment. 121(1). 121–131. 163 indexed citations

12.

Chen, Chien‐Chih, et al.. (2010). Is it appropriate to apply the enhanced recovery program to patients undergoing laparoscopic rectal surgery?. Surgical Endoscopy. 25(5). 1477–1483. 18 indexed citations

13.

Cheng, Skye Hung‐Chun, Cheng‐Fang Horng, Mei‐Chun Lu, et al.. (2009). Adherence to Quality Indicators and Survival in Patients With Breast Cancer. Medical Care. 47(2). 217–225. 58 indexed citations

14.

Hsu, Li‐Han, et al.. (2006). Intrapleural Urokinase for the Treatment of Loculated Malignant Pleural Effusions and Trapped Lungs in Medically Inoperable Cancer Patients. Journal of Thoracic Oncology. 1(5). 460–467. 33 indexed citations

15.

Lee, Ming-Yuan, Tran‐Der Tan, An‐Chen Feng, & Mei-Ching Liu. (2006). Clinicopathological analysis of 598 malignant lymphomas in Taiwan: Seven-year experience in a single institution. American Journal of Hematology. 81(8). 568–575. 35 indexed citations

16.

Hsu, Li‐Han, et al.. (2006). Intrapleural Urokinase for the Treatment of Loculated Malignant Pleural Effusions and Trapped Lungs in Medically Inoperable Cancer Patients. Journal of Thoracic Oncology. 1(5). 460–467. 10 indexed citations

17.

Chen, Chien‐Chih, et al.. (2005). Transanal local wide excision for rectal adenocarcinoma.. PubMed. 52(62). 460–3. 2 indexed citations

18.

Cheng, Skye Hongiun, Mei-Hua Tsou, Mei-Ching Liu, et al.. (2000). Unique features of breast cancer in Taiwan. Breast Cancer Research and Treatment. 63(3). 213–223. 93 indexed citations

19.

Cheng, Jason Chia‐Hsien, et al.. (2000). Locoregional recurrence in patients with one to three positive axillary nodes after mastectomy without adjuvant radiotherapy.. PubMed. 99(10). 759–65. 4 indexed citations

20.

Lee, Ti‐Kai, Yee‐Chun Chen, Tsung‐Li Kuo, et al.. (1989). Effect of low dose acetylsalicylic acid upon plasma thromboxane B2 levels and platelet aggregation in ischemie stroke patients. Clinica Chimica Acta. 184(3). 323–328. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact